# Daejin Abidoye, M.D.

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/daejin-abidoye-md
Canonical HTML page: https://gethealthbrief.com/entity/daejin-abidoye-md

## Recent coverage (1 stories)

### Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
2026-07-11 23:08:35 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Full story: https://gethealthbrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-60-percent-risk-reduction-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.